male-dr

Leading the world in
early cancer detection research

Our innovative cancer screening
studies mean better outcomes for patients

female-dr

Innovation in cancer research
and development

We are changing the face of cancer detection
and treatment using the latest
advancements in Metabolomics

female-dr

Non-invasive and affordable early
cancer screening and monitoring
solution

90% of cancers are curable if caught early
Your Health is Our Focus!

Early cancer detection research for a better future

BIOMARK’S MISSION

To provide universal access to a new paradigm in cancer diagnostics using metabolomics.

WHAT IS A BIOMARKER?

According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:

  • proteins (e.g. an enzyme or receptor)
  • nucleic acids (e.g. a microRNA or other non-coding RNA)
  • antibodies
  • and peptides among other categories

A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.

POTENTIAL CLINICAL USES OF CANCER BIOMARKERS

Biomarkers have many potential applications in oncology including:

  • Estimating risk of cancer
  • Screening for occult primary cancers
  • Distinguishing benign from malignant findings or one type of malignancy from another
  • Monitoring status of the disease either to detect recurrence or determine response or progression to therapy
  • Personalizing a treatment program especially for immunotherapy applications
  • Help in assessing pseudo progression with imaging modalities

VIDEOS: CANCER EDUCATION

LATEST NEWS

National research team targets glioblastoma

31

May, 2019

National research team targets glioblastoma

By: | Tags:

MAY 31, 2019 —  Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and is characterized by its infiltrative and often fatal progression. The strikingly poor survival for patients with GBM of 14-16 months following diagnosis is due in part to limited early detection methods and an absence of effective treatment options. Funding from the Canadian Institute of Health Research of $753,432 was awarded to professor Donald Miller…

READ MORE

NEWS RELEASES

BIOMARK ANNOUNCES PRIVATE PLACEMENT

November 21, 2019

Vancouver, British Columbia – (November 21st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 1,666,667 Units at a price of $0.30 to raise gross proceeds of up to $500,000.   Each Unit is composed of one common share (a “Share”) of the Company and one-half Share purchase warrant (a “Warrant”). Each whole Warrant shall entitle the holder to acquire one Share at a price of $0.45 per Share for […]


READ MORE

STOCK QUOTE

BIOMARK AWARDS, GRANTS, RECOGNITIONS

BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.

Read More